{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:03:14Z","timestamp":1784808194609,"version":"3.55.0"},"reference-count":18,"publisher":"Jaypee Brothers Medical Publishing","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.59556\/japi.74.1559","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:23:36Z","timestamp":1781601816000},"page":"88-92","source":"Crossref","is-referenced-by-count":0,"title":["Antiretroviral Therapy in India (2025): Drugs, Indications, Contraindications, Mechanisms, and Prophylaxis (PEP\/PrEP)"],"prefix":"10.59556","volume":"74","author":[{"given":"Rajesh","family":"Deshwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"key":"key20260723112441_B1","volume-title":"National guidelines for HIV care and treatment.","author":"National AIDS Control Organization (NACO).","year":"2021."},{"key":"key20260723112441_B2","volume-title":"National technical guidelines on anti-retroviral treatment.","author":"National AIDS Control Organization (NACO).","year":"2018."},{"key":"key20260723112441_B3","author":"World Health Organization (WHO).","year":"2024."},{"key":"key20260723112441_B4","author":"World Health Organization (WHO).","year":"2024."},{"key":"key20260723112441_B5","volume-title":"Revised national guidelines for post-exposure prophylaxis for HIV.","author":"National AIDS Control Organization (NACO).","year":"2024."},{"key":"key20260723112441_B6","volume-title":"Operational circular on PEP medicines and DTG-aligned PEP dosing.","author":"Employees' State Insurance Corporation (ESIC).","year":"2024."},{"key":"key20260723112441_B7","volume-title":"National technical guidelines for pre-exposure prophylaxis (PrEP).","author":"National AIDS Control Organization (NACO).","year":"2016."},{"key":"key20260723112441_B8","unstructured":"PrEPWatch. (2022). India National Technical Guidelines for PrEP, 2022. [online] Available from: https:\/\/www.prepwatch.org\/resources\/india-national-technical-guidelines-for-prep-2022\/ [Last accessed May, 2026]."},{"issue":"(4):","key":"key20260723112441_B9","doi-asserted-by":"crossref","first-page":"413.","DOI":"10.3390\/healthcare12040413","article-title":"Revolutionizing HIV-1 viral load monitoring in India: the potential of dried blood spot analysis for expanding access and improving care.","volume":"12","author":"Chandane Tak","year":"2024;","journal-title":"Healthcare (Basel)"},{"issue":"(3):","key":"key20260723112441_B10","first-page":"e56424.","article-title":"Adverse drug reactions and prescription patterns of antiretroviral drugs: a longitudinal observational study from a tertiary care hospital in western India.","volume":"16","author":"Sekar","year":"2024;","journal-title":"Cureus"},{"issue":"(6):","key":"key20260723112441_B11","first-page":"527\u2013","article-title":"What will it take to expand the pre-exposure prophylaxis to prevent new HIV infections in India?","volume":"160","author":"Gaur","year":"2024;","journal-title":"Indian J Med Res"},{"key":"key20260723112441_B12","doi-asserted-by":"crossref","first-page":"541\u2013","DOI":"10.15585\/mmwr.mm7435a1","article-title":"Clinical recommendation for the use of injectable lenacapavir as HIV preexposure prophylaxis\u2014United States, 2025.","volume":"74:","author":"Patel","year":"2025;","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key20260723112441_B13","volume-title":"FDA approval of injectable lenacapavir marks progress for HIV prevention.","author":"World Health Organization (WHO).","year":"2025."},{"key":"key20260723112441_B14","unstructured":"Reuters. (2025). US FDA approves Gilead's twice-yearly injection for HIV prevention (lenacapavir\/Yeztugo). [online] Available from: https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/us-fda-approves-gileads-twice-yearly-injection-hiv-prevention-2025-06-18\/ [Last accessed May, 2026]."},{"key":"key20260723112441_B15","volume-title":"Yeztugo (lenacapavir) FDA approval announcement.","author":"Gilead Sciences.","year":"2025."},{"issue":"(1):","key":"key20260723112441_B16","first-page":"e407.","article-title":"PrEP in India's HIV prevention policy in the era of social media and sex positivity.","volume":"9","author":"Kar","year":"2020;","journal-title":"Cent Asian J Glob Health"},{"key":"key20260723112441_B17","volume-title":"National HIV counseling and testing guidelines.","author":"National AIDS Control Organization (NACO).","year":"2024."},{"key":"key20260723112441_B18","unstructured":"National AIDS Control Organization (NACO). 2021. National Guidelines for HIV Care and Treatment. New Delhi: Ministry of Health and Family Welfare, Government of India. Available from: https:\/\/www.differentiatedservicedelivery.org\/wp-content\/uploads\/National_Guidelines_for_HIV_Care_and_Treatment_2021.pdf."}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:24:53Z","timestamp":1784805893000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-74-6-88"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.59556\/japi.74.1559"],"URL":"https:\/\/doi.org\/10.59556\/japi.74.1559","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}